HPSE2在胃腺癌组织中的表达及对胃癌细胞侵袭迁移的影响

胡家熙; 唐波; 唐黎; 杨敏; 汪苏敏; 杨仕明

doi:10.16016/j.1000-5404.202001184

您当前的位置：

首页 >

文章列表页 >

HPSE2在胃腺癌组织中的表达及对胃癌细胞侵袭迁移的影响

临床医学 | 更新时间：2026-01-09

- HPSE2在胃腺癌组织中的表达及对胃癌细胞侵袭迁移的影响
- Expression of heparanase-2 in gastric adenocarcinoma tissues and its effect on invasion and migration of gastric cancer cells
- 第三军医大学学报 2020年42卷第10期页码：1015-1021
- 作者机构：
  
  400037 重庆陆军军医大学(第三军医大学)第二附属医院消化内科
- 作者简介：
  
  [杨仕明，电话: (023) 68765184，E-mail: shimingyang@yahoo.comYANG Shiming, Tel: 86-23-68765184, E-mail: shimingyang@yahoo.com
- 基金信息：
- DOI：10.16016/j.1000-5404.202001184
  中图分类号： R345;R73-37;R735.2
- 收稿：2020-01-22，
  
  修回：2020-03-15，
  
  纸质出版：2020-05-30
- 稿件说明：
移动端阅览
胡家熙, 唐波, 唐黎, 等. HPSE2在胃腺癌组织中的表达及对胃癌细胞侵袭迁移的影响[J]. 第三军医大学学报, 2020,42(10):1015-1021.

Jiaxi HU, Bo TANG, Li TANG, et al. Expression of heparanase-2 in gastric adenocarcinoma tissues and its effect on invasion and migration of gastric cancer cells[J]. Journal of Third Military Medical University, 2020, 42(10): 1015-1021.
胡家熙, 唐波, 唐黎, 等. HPSE2在胃腺癌组织中的表达及对胃癌细胞侵袭迁移的影响[J]. 第三军医大学学报, 2020,42(10):1015-1021. DOI： 10.16016/j.1000-5404.202001184.

Jiaxi HU, Bo TANG, Li TANG, et al. Expression of heparanase-2 in gastric adenocarcinoma tissues and its effect on invasion and migration of gastric cancer cells[J]. Journal of Third Military Medical University, 2020, 42(10): 1015-1021. DOI： 10.16016/j.1000-5404.202001184.

摘要

目的

探讨HPSE2在胃癌组织中的表达及其对胃癌生存预后及胃癌细胞侵袭迁移的影响。

方法

将胃腺癌组织芯片进行HPSE2的免疫组化染色，检测其在癌及癌旁组织中的表达，分析其表达水平与胃癌临床特征、生存预后及预后影响因素的关系。构建HPSE2过表达载体，转染胃癌细胞建立HPSE2过表达细胞，Transwell实验检测HPSE2过表达对胃腺癌细胞迁移和侵袭的影响。

结果

HPSE2在胃腺癌组织的平均病理评分为4.56，癌旁组织为7.18，HPSE2在胃腺癌组织中的表达显著低于癌旁组织(

0.05)。HPSE2的表达水平与肿瘤大小、淋巴结转移及临床分期相关，并且HPSE2蛋白高表达患者的中位生存时间和累积生存率均显著高于低表达患者(

0.05)。Cox比例风险模型结果显示，临床分期、肿瘤大小和HPSE2蛋白表达是影响胃腺癌患者预后的风险因素(

0.05)。胃癌细胞过表达HPSE2可明显抑制胃癌细胞的侵袭和迁移。

结论

HPSE2蛋白在胃腺癌组织低表达，与肿瘤大小、临床分期及患者的生存预后相关，HPSE2过表达可明显抑制胃癌细胞的侵袭迁移能力。

Abstract

Objective

To investigate the expression of heparanase-2 (HPSE2) in gastric cancer tissues

and explore its effect on the survival and prognosis of the cancer and invasion and migration of the cancer cells.

Methods

Immunohistochemical staining of HPSE2 was performed on gastric cancer tissue chip to examine the expression level of HPSE2 in gastric cancer and paracancerous tissues. The correlation of HPSE2 expression level with clinical features

survival

prognosis and prognostic factors were analyzed. The lentival vectors of HPSE2 overexpression were constructed

and then transfected in gastric cancer cell lines SGC7901 and MKN28. The effect of HPSE2 overexpression on invasion and migration of gastric cancer cells were detected using Transwell analysis.

Results

The mean pathological score of HPSE2 was 4.56 in gastric cancer tissue

and 7.18 in paracancer tissues

showing that the expression was significantly lower in gastric cancer than paracancer tissues (

0.05). The expression level of HPSE2 was closely correlated with the tumor size

lymph node metastasis

and clinical staging. The patients with higher HPSE2 expression had obviously shorter median survival time and cumulative survival rate than those with lower expression (

0.05). Cox proportional risk model showed that clinical stage

tumor size and HPSE2 protein expression were risk factors for prognosis of gastric cancer patients (

0.05). Overexpression of HPSE2 could remarkably inhibit the invasion and migration of gastric cancer cells.

Conclusion

HPSE2 is lowly expressed in gastric cancer tissues

and is associated with the tumor size

lymph node metastasis

survival and prognosis of gastric cancer. Overexpression of HPSE2 could inhibit the invasion and migration of gastric cancer cells.

关键词

Keywords

references

CHEN W, ZHENG R, BAADE P D, et al . Cancer statistics in China, 2015[J ] . CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.

BENCIVENGA M, VERLATO G, HAN D S, et al . Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer[J ] . Bri J Surg, 2017, 104(9): 1235-1243. DOI: 10.1002/bjs.10551.

VLODAVSKY I, GROSS-COHEN M, WEISSMANN M, et al . Opposing functions of heparanase-1 and heparanase-2 in cancer progression[J ] . Trends Biochem Sci, 2018, 43(1): 18-31. DOI: 10.1016/j.tibs.2017.10.007.

VLODAVSKY I, SINGH P, BOYANGO I, et al . Heparanase: From basic research to therapeutic app lications in cancer and inflammation[J ] . Drug Resistance Updates, 2016, 29: 54-75. DOI: 10.1016/j.drup.2016.10.001.

CHEN X, ZHAO H, CHEN C, et al . The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation[J ] . Oncol Lett, 2020, 19(1): 211-220. DOI: 10.3892/ol.2019.11121.

VORNICOVA O, BOYANGO I, FELD S, et al . The prognostic significance of heparanase expression in metastatic melanoma[J ] . Oncotarget, 2016, 7(46): 74678-74685. DOI: 10.18632/oncotarget.12492.

SHAH S, FOURGEAUD C, DERIEUX S, et al . The close relationship between heparanase and epithelial mesenchymal transition in gastric signet-ring cell adenocarcinoma[J ] . Oncotarget, 2018, 9(73): 33778. DOI: 10.18632/oncotarget.26042.

JIN H, CUI M. New advances of heparanase and heparanase-2 in human diseases[J]. Arch Med Res, 2018, 49(7): 423-429. DOI: 10.1016/j.arcmed.2019.02.004.

LEVY-ADAM F, FELD S, COHEN-KAPLAN V, et al . Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity[J ] . J Biol Chem, 2010, 285(36): 2 8010-28019. DOI: 10.1074/jbc.M110.116384.

MARQUES R M, FOCCHI G R, THEODORO T R, et al . The immunoexpression of heparanase 2 in normal epithelium, intraepithelial, and invasive squamous neoplasia of the cervix[J ] . J Low Genit Tract Dis, 2012, 16(3): 256-262. DOI: 10.1097/LGT.0b013e3182422c69.

WHITEHEAD M J, MCGONIGAL R, WILLISON H J, et al . Heparanase attenuates axon degeneration following sciatic nerve transection[J ] . Sci Rep, 2018, 8(1). DOI: 10.1038/s41598-018-23070-6.

GROSS-COHEN M, FELD S, DOWECK I, et al . Heparanase 2 attenuates head and neck tumor vascularity and growth[J ] . Cancer Res, 2016, 76(9): 2791-2801. DOI: 10.1158/0008-5472.CAN-15-1975.

LV B, ZHANG B, HU X Y, et al . Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma[J ] . Oncol Lett, 2016, 11(2): 1327-1334. DOI: 10.3892/ol.2016.4085..

FU J, KHAYBULLIN R, ZHANG Y, et al . Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast ca ncer progression[J ] . BMC Cancer, 2015, 15(1). DOI: 10.1186/s12885-015-1410-y.

GARCÍA B, MARTÍN C, GARCÍA-SUÁREZ O, et al . Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease[J ] . J Alzheimer's Dis, 2017, 58(1): 185-192. DOI: 10.3233/JAD-161298.

ROBERTS N A, HILTON E N, LOPES F M, et al . Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder[J ] . Kidney Int, 2019, 95(5): 1138-1152. DOI: 10.1016/j.kint.2018.11.040.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

奥沙利铂通过诱导胃癌细胞铜死亡抑制胃癌

LncRNA FGD5-AS1通过调节miR-302b-3p/E2F1轴对胃癌细胞迁移及侵袭的影响

转录因子TGIF1高表达胃癌的免疫抑制性微环境特征及临床意义分析

内镜下LCPL征象对胃黏膜高危肠上皮化生的诊断价值

钙腔蛋白对胃癌迁移、侵袭及患者预后的影响